MAP2K7 and thyroid gland undifferentiated (anaplastic) carcinoma: The following co-cited articles involved an open-label trial of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) combination therapy in BRAF V600E-mutated anaplastic thyroid cancer (23).